Skip to main
ALLO

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics is viewed positively due to its strong pipeline of cell therapies that demonstrate the potential for significant levels of efficacy and safety in treating cancer and autoimmune disorders. The company's reliance on partners for access to gene-editing technology could pose risks, but the recent stock price decline presents an attractive entry point for investors, especially after the positive interim futility results from the ALPHA3 trial for cema-cel. Additionally, the high MRD-negativity rate observed in the trial could potentially lead to a new therapy benchmark for 1L DLBCL patients. However, the company will need additional funding to support the development and commercialization of its product candidates.

Bears say

Allogene Therapeutics is facing potential setbacks in its main product candidate cema-cel, with a bear case scenario lowering its probability of success to 5%. This results in a reduced fair value of $1, highlighting the high risk involved in investing in the company. Additionally, the company's DCF-based valuation methodology projects a total firm value of $3.76B, resulting in a price objective of $12 per share, with potential risks including durability challenges and manufacturing issues.

ALLO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 9 analysts, ALLO has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.